Bevacizumab in endometrial cancer treatment

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 649-658

  Morotti, Matteo ^a   Valenzano Menada, Mario ^a   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

antiangiogenic agents; bevacizumab; endometrial cancer; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; IXABEPILONE; PACLITAXEL; TEMSIROLIMUS; VASCULOTROPIN;

ABDOMINAL SURGERY; ABSCESS; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOMETRIUM CANCER; EPISTAXIS; FATIGUE; FISTULA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MAJOR SURGERY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RECURRENT CANCER; REVIEW; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VOLUME; URINARY EXCRETION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 84859570712     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.672558     Document Type: Review

References (74)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
2. Evans T, Sany O, Pearmain P, et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 2011;104:1505-10
3. Zighelboim I, Powell MA. Adjuvant treatment for early-stage endometrial cancer. Clin Obstet Gynecol 2011;54:245-55
4. Lee NK. Adjuvant treatment of advanced-stage endometrial cancer. Clin Obstet Gynecol 2011;54:256-65
5. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006;66:3303-9
6. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18
7. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis- dependent? J Pathol 2004;202:5-13 (Pubitemid 38072840)
8. National Cancer Institute. FDA Approval for Bevacizumab. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Accessed 26 June 2011]
9. Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologicals 2011;5:1-5
10. Del Carmen M, Boruta D, Schorge J. Recurrent endometrial cancer. Clin Obstet Gynecol 2011;54:266-77
11. Mountzios G, Pectasides D, Bournakis E, et al. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 2011;79:278-92
12. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20 (Pubitemid 46359618)
13. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4 (Pubitemid 27193480)
14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10 This review discusses the clinical relevance and need for biomarkers in the evaluation of angiogenesis inhibitors. (Pubitemid 37328844)
15. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64 (Pubitemid 26272076)
16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76 Provides detailed description of VEGF receptors and signaling. (Pubitemid 36749215)
17. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12 (Pubitemid 30070735)
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27 Excellent overview of angiogenesis factors and targets for therapy. (Pubitemid 46202320)
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49 (Pubitemid 351656458)
20. Shahi PK, Pineda IF. Tumoral angiogenesis: review of the literature. Cancer Invest 2008;26:104-8
21. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res 2001;21:4383-8 Overview of angiogenesis processes in endometrial cancer for therapy. (Pubitemid 34240969)
22. Rogers PA, Donoghue JF, Walter LM, et al. Endometrial angiogenesis, vascular maturation, and lymphangiogenesis. Reprod Sci 2009;16:147-51
23. Rogers PAW, Lederman FL, Taylor N. Endometrial microvascular growth in normal and dysfunctional states. Hum Reprod Update 1998;4:503-8 (Pubitemid 29041462)
24. Gargett CE, Rogers PAW. Human endometrial angiogenesis. Rev Reprod 2001;121:181-6 (Pubitemid 32175540)
25. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000;6:45-55 (Pubitemid 30099342)
26. Torry DS, Torry RJ. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am J Reprod Immunol 1997;37:21-9 (Pubitemid 27075965)
27. Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999;72:220-31 (Pubitemid 29093779)
28. Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996;78:454-60 (Pubitemid 26250531)
29. Yokoyama Y, Sato S, Futagami M, et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000;77:413-18 (Pubitemid 30368560)
30. Dai H, Zhao S, Xu L, et al. Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. Oncol Rep 2010;23:795-9
31. Holland CM, Day K, Evans A, et al. Expression of the VEGF and angiopoietin genes in atypical hyperplasia and endometrial cancer. Br J Cancer 2003;89:891-8 (Pubitemid 37175813)
32. Erdem O, Erdem M, Erdem A, et al. Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer 2007;17:1327-32 (Pubitemid 350077361)
33. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95 A preclinical study using human samples and an endometrioid orthotopic mouse model that evaluated the significance of VEGF in EC.
34. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006;66:3303-9
35. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt- 1 and KDR/fl k-1) as prognostic indicators in endometrial carcinoma. Tumor Biol 2005;26:81-7 (Pubitemid 40827608)
36. Fujimoto J, Ichigo S, Hirose R, et al. Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett 1998;134:15-22
37. Fine BA, Valente PT, Feinstein GI, et al. VEGF, Flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 2000;76:33-9
38. Espinosa I, Jose Carnicer M, Catasus L, et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol 2010;34:1708-14
39. Ozuysal S, Bilgin T, Ozan H, et al. Angiogenesis in endometrial carcinoma: correlation with survival and clinicopathologic risk factors. Gynecol Obstet Invest 2003;55:173-7 (Pubitemid 36928638)
40. Topolovec Z, Corusic A, Babic D, et al. Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer. Coll Antropol 2010;34:447-53
41. Mannelqvist M, Stefansson IM, Bredholt G, et al. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 2011;178:861-71
42. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32:2474-84
43. Kaku T, Kamura T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997;80:741-7 (Pubitemid 27339830)
44. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-90 (Pubitemid 29220843)
45. Felix A, Weissfeld J, Edwards R, et al. Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol 2010;31:139-44
46. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80 (Pubitemid 40216420)
47. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7:433-45 (Pubitemid 46681799)
48. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50 (Pubitemid 32119100)
49. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-8 (Pubitemid 29113511)
50. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802 (Pubitemid 46038527)
51. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24 (Pubitemid 37433402)
52. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009;43:490-501
53. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BriTE). J Clin Oncol 2006;24:3536
54. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-7
55. Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010;23:460-8
56. Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21:1381-9
57. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). J Clin Oncol 2008;26:204
58. Ranpura V, Hapani V, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (Madr) 2010;49:287-97
59. Schutz FA, Jardim DL, Je Y, et al. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer 2011;47:1161-74
60. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010;15:1179-91
61. Davies S, Dai D, Pickett G, et al. Effects of bevacizumab in mouse model of endometrial cancer: defining the molecular basis for resistance. Oncol Rep 2011;25:855-62
62. Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27:3525-8 First report of bevacizumab for the treatment of recurrent uterine cancer. (Pubitemid 47607497)
63. Reinhardt J, Schott S, Mayer C, et al. Long-term remission of an advanced recurrent endometrial cancer in a heavily pretreated patient using a combined regimen with bevacizumab and metronomic cyclophosphamide. Anticancer Drugs 2011;22:822-4
64. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2011;29:2259-65 First Phase II trial evaluating the use of bevacizumab in the treatment of recurrent EC.
65. Viswanathan AN, Szymonifka J, Tanaka C, et al. The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol 2011;29:5101
66. Available from: http://clinicaltrials.gov/ct2/show/NCT00723255?term= bevacizumab+endometrial&rank=7
67. Available from: http://clinicaltrials.gov/ct2/show/NCT00513786?term= bevacizumab+endometrial&rank=3
68. Available from: http://clinicaltrials.gov/ct2/show/NCT00977574?term= bevacizumab+endometrial&rank=1
69. Available from: http://clinicaltrials.gov/ct2/show/NCT01010126
70. Available from: http://clinicaltrials.gov/ct2/show/NCT00462826?term= vegf+trap+endometrial&rank=1
71. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
72. Perren TJ, Swart AM, Pfisterer J, et al. A phase III trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
73. Raja FA, Hook JM, Ledermann JA. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev 2011; [Epub ahead of print]
74. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34